Alector is a high-risk biotech reset whose future now hinges almost entirely on whether its blood-brain barrier platform can recover value after repeated neurodegeneration trial failures.
Overview
Alector is a clinical-stage biotech that pioneered immuno-neurology but has been forced into a major strategic reset after three late-stage clinical failures. Its former GSK and AbbVie collaborations have collapsed or become non-performing, leaving minimal revenue and no commercial products. The company’s entire value proposition now rests on its proprietary blood-brain barrier crossing technology, the Alector Brain Carrier platform, aimed at Alzheimer’s, Parkinson’s, and dementia markets. The opportunity is large, but the company is early, cash-burning, partner-dependent, and highly speculative.